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Case report

Desperate times, desperate measures: successful use
of chemotherapy in treatment of haemophagocytic
lymphohistiocytosis (HLH) due to
disseminated histoplasmosis
Sunny Rajendra Kumar Singh, Kannan Thanikachalam, Vijayalakshmi Donthireddy
SUMMARY
We describe a case of haemophagocytic
lymphohistiocytosis (HLH) secondary to disseminated
histoplasmosis, which was treated with chemotherapy in
Correspondence to
addition to standard antifungal therapy. While HLH in the
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setting of infections is very well described, its treatment
ssingh15@hfhs.o rg
in this setting is controversial, with some physicians
treating only the underlying infection, whereas others
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using immune suppression in addition to antimicrobials.
To the best of our knowledge, this is the first report
documenting the successful treatment of an adult patient
with HLH due to disseminated histoplasmosis using
etoposide chemotherapy after initial antifungal therapy
failed to show improvement.
Haematology and Oncology,
Henry Ford Hospital, Detroit,
Michigan, USA
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Haemophagocytic lymphohistiocytosis (HLH) is
a life-
threatening hyperinflammatory syndrome
resulting from a hyper stimulated but ineffective
immune response. It is characterised by impaired
function of natural killer (NK) cells and cytotoxic
T lymphocytes (CTLs) that results in an unchecked
inflammatory response. Without treatment, HLH
has an estimated overall mortality of 58%–75%.1
The disorder is divided into primary (genetic) and
secondary (reactive) haemophagocytic syndrome.
The primary genetic disorder (familial/genetic
HLH) is associated with defects in cytotoxic functioning of NK cells and CTLs and is common in
children.2 Much of the understanding of HLH in
adults is based on research done in paediatric population.3 The secondary or reactive haemophagocytic
syndrome is common in adults and is associated with
infections, malignancy or an autoimmune disorder
(macrophage activating syndrome).2 Since there is
no single definitive test, the diagnosis of HLH is
made on the basis of criteria taking into account
clinical, laboratory and histopathological findings.
Histopathologically, typical findings include activated macrophages with engulfed leucocytes, erythrocytes, platelets and their precursors cells. These
activated macrophages are known as haemophagocytes and they may be seen in any organ, particularly in the bone marrow, lymph nodes, liver and
spleen.2 In HLH-94, the first prospective international treatment study for HLH, diagnosis was based
on five criteria (fever, splenomegaly, bicytopenia,

hypertriglyceridaemia and/or hypofibrinogenaemia,
and haemophagocytosis). In HLH-2004, three
additional criteria were introduced: low/absent NK
soluble
cell activity, hyperferritinaemia and high-
interleukin (IL) 2 receptor levels. Altogether five of
these eight criteria must be fulfilled, unless family
history or molecular diagnosis is consistent with
HLH.4 Since therapy can be lifesaving and some of
the clinical criteria occur late in the disease, it is
not necessary to fulfil all criteria before initiating
therapy.2 The treatment of HLH involves the use
of corticosteroids, chemotherapy or other drugs to
block the hyperinflammatory response and specific
therapy for the underlying cause. The treatment
protocol as per HLH-2004 includes the upfront
use of dexamethasone, etoposide and cyclosporine.
Methotrexate and steroids may be given intrathecally in situations where central nervous system
involvement is suspected. Haematopoietic stem
cell transplantation is also a treatment option for
certain groups of patients. These include patients
whose disease is familial or due to a molecular risk
factor and in those who have severe, persistent or
reactivated disease.4

CASE PRESENTATION

A 44-year-old woman with medical history of ankylosing spondylitis, hypertension, nephrolithiasis,
fibromyalgia and obesity presented with 5 days of
fever, nausea and upper abdominal pain. She was
receiving methotrexate 10 mg weekly for ankylosing spondylitis and was started on infliximab
(400 mg intravenous infusion) about a month prior
to her presentation. She had previously been on
prednisone and hydroxychloroquine. She denied
using tobacco products, alcohol or drugs and had
used cannabis occasionally. On examination, she
was haemodynamically stable with a temperature
of 102° F, jaundiced and had a diffusely tender
abdomen. Her initial laboratory tests are listed in
table 1. During evaluation of elevated liver function tests, abdominal ultrasound and CT revealed
gall bladder wall oedema and gallstone without
dilation of the common bile duct. Hepatobiliary
iminodiacetic acid (HIDA) scan was non-diagnostic
and magnetic resonance cholangiopancreatography (MRCP) showed a contracted gall bladder
along with non-
obstructed biliary system. Viral
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Table 1

Laboratory results at the time of presentation

Laboratory parameter

Value

Normal range

Haemoglobin

97 g/L

120–155 g/L

White blood cell count

7.6×109/L

3.5–10.5×109/L

Platelets

179×109/L

150–450×109/L

Serum creatinine

0.6 mg/dL

0.52–1.04 mg/dL

Sodium

134 mmol/L

137–145 mmol/L

Bicarbonate

21 mmol/L

22–30 mmol/L

Total bilirubin (direct bilirubin)

6.9 mg/dL (6.2 mg/dL) 0.2–1.3 mg/dL (0–0.4 mg/
dL)

Aspartate aminotransferase

445 U/L

14–36 U/L

Alanine aminotransferase

141 U/L

9–52 U/L

Alkaline phosphatase

544 U/L

38–126 U/L

Prolactin

85.2 ng/mL

3–18.6 ng/mL

Prothrombin time

15.2 s

12.1–14.5 s

Partial thromboplastin time

30 s

22–36 s

International normalised ratio

1.23

<1.1

hepatitis A, B and C and HIV were ruled out. Blood and urine
cultures were ordered and intravenous antibiotics were started
for suspected biliary source of infection. Because there was no
convincing evidence of biliary obstruction, interventions to drain
the biliary system were withheld. Over the next 72–96 hours,
fever worsened (to around 103°F–104°F) and she had an episode
of seizure, persistent encephalopathy, acute kidney injury
(requiring sustained low efficiency dialysis), coagulopathy and
worsening liver function. Electroencephalogram (EEG) showed
triphasic waves and background slowing consistent with metabolic encephalopathy. A chest X-ray (figure 1) done for tachypnoea showed possible multifocal pneumonia and soon enough,
she needed intubation for airway protection and vasopressors
for hypotension. Also, given the persistent fevers and encephalopathy, differential diagnosis and management were broadened for the possibility of meningitis and viral encephalitis.
CT of the head showed cerebral oedema and lumbar puncture
showed intracranial pressure of 41 cm H2O (5–18 cm H2O),
white blood cell count of 12/mL (0–5/mL) and protein of 51 mg/

Figure 1 Chest X-ray (anteroposterior) done during the initial workup
showing bilateral multifocal pneumonia.
2

dL (15–55 mg/dL). Cerebrospinal fluid (CSF) PCR and cultures
were negative for bacterial, fungal and viral infections. Given the
incessant high fevers, continued clinical deterioration and negative microbial cultures, possibility of HLH was raised and appropriate workup was ordered. Initial workup for HLH revealed
a ferritin level of 20 308 ng/mL (11–307 ng/mL), triglyceride
level of 1409 mg/dL (40–200 mg/dL), fibrinogen level of 105 mg/
dL (200–450 mg/dL) and a repeat CT scan showed mild splenomegaly. Patient fulfilled five out of eight criteria for HLH,
namely, fever, cytopenia, splenomegaly, elevated ferritin and
elevated triglyceride or low fibrinogen. She was started on
dexamethasone 20 mg daily for concern of HLH. A liver biopsy
done for worsening liver function showed granulomatous hepatitis and numerous intracellular organisms within macrophages
and hepatocytes, which were morphologically compatible with
Histoplasma capsulatum. Grocott methenamine silver (GMS)
stain highlighted fungal yeast forms and given that these findings were consistent with disseminated histoplasmosis, she was
started on amphotericin. Histoplasma antigen level in urine was
≥19.0 ng/mL, which was above the limit of quantification for
the assay. Despite being on amphotericin and dexamethasone for
4 days, she did not show clinical improvement. She was started
on etoposide in addition to the dexamethasone per HLH-94
protocol. A bone marrow biopsy done before initiating chemotherapy showed fungal yeast forms on GMS stain and erythrophagocytosis. Etoposide was dose reduced to 25% of original
(37.5 mg/m2) due to acute kidney injury and it was continued
for a total of 2 doses only given the rapid clinical improvement.

OUTCOME AND FOLLOW-UP

Over the ensuing days, the patient improved dramatically while
being carefully monitored and supported in the intensive care unit.
She was eventually discharged in 2 weeks from the first dose of
etoposide with the plan for dexamethasone taper over 4 weeks and
long-term antifungal therapy. Soluble IL-2 receptor levels, which
were sent earlier, eventually came back elevated to 24 900 pg/mL
(≤1033 pg/mL) consistent with the diagnosis of HLH.

DISCUSSION

Patients with HLH present with clinical and laboratory evidence of
extreme inflammation.5 HLH is categorised as primary (familial)
or secondary (acquired) and occasionally, when an inciting event
is not identified, it is considered idiopathic. Also, many patients
are thought to have underlying genetic susceptibility, which predisposes them to develop HLH.3 In a large study from France done
on 162 adults with HLH, the most common associated conditions were malignancy (60%), infection (25%) and autoimmune
disorders (3%). The most common malignancy in this cohort was
B-
cell lymphoma (22%) and the most prevalent infection was
Mycobacterium (8%). Notably, nearly half of these patients were
immunosuppressed at presentation due to either HIV infection
or immunosuppressive therapy.6 In a retrospective study done
on 62 adults with HLH, the most common malignancy observed
was T-cell lymphoma (59%) and the most frequent infection was
Epstein-Barr virus (EBV) (26%).7 In our patient, the inciting event
was immunosuppression from the use of infliximab, which led to
disseminated histoplasma infection resulting in an extreme inflammatory state consistent with HLH. Opportunistic infections (OIs)
are well known to be associated with the use of biologic disease-
modifying antirheumatic drugs, especially tumour necrosis factor
(TNF) inhibitors. Different agents within this group vary in their
strength of association with OIs. For example, infliximab and
adalimumab have a higher risk of OIs compared with etanercept.8
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TNF is necessary for forming granulomas and preventing reactivation of granulomatous infections. Of note, histoplasmosis is the
most common fungal OI with an estimated incidence of 18.78 per
100 000 persons (0.00018%), second only to tuberculosis with an
incidence of 53.81 per 100 000 persons (0.00053%) treated with
infliximab.9 Clinical features of disseminated histoplasmosis could
overlap with that of HLH in many aspects, including prolonged
fever, hepatosplenomegaly, pancytopenia and coagulopathy. Given
the similarity in manifestations, it may be challenging to differentiate these two conditions without specialised testing.10 In our case,
the liver biopsy which led to the diagnosis of disseminated histoplasma was prompted by the persistently abnormal liver function
tests. There are several cases in the literature describing association of HLH with underlying histoplasmosis; however, majority
are in the setting of HIV infection.11 Management of HLH in the
setting of infection is controversial. Antimicrobial therapy alone
might be sufficient if a treatable inciting infection is identified.
However, for those who are critically ill or clinically worsening,
concurrent immunosuppressive therapy could also be used.12 The
seriousness of the condition is highlighted in a review of 18 HIV
patients presenting with HLH in the setting of disseminated histoplasmosis, where 44.4% patients died. Not getting antifungal treatment and having Histoplasma in blood were the two main risk
factors for death. None of the survivors among these were treated
with chemotherapy or bone marrow transplant.11 Use of anakinra,
an IL-1 receptor antagonist, and dexamethasone to treat secondary
HLH in a patient with HIV/AIDS and disseminated histoplasmosis
that was refractory to concurrent antifungals, highly active antiretroviral therapy (HAART) and intravenous immunoglobulin (IVIG)
has been described.13

The treatment of HLH in principle includes eliminating any
possible underlying trigger and regulating the overactive immune
system. For example, if an infection or malignancy is identified,
patients should be promptly started on the appropriate therapy
and this may occasionally be sufficient to halt the immune dysregulation. On the other hand, in those with known genetic predisposition or EBV infection or in situations where a clear trigger is
not apparent, an etoposide-based regimen should be initiated as
soon as possible.3 Disseminated histoplasmosis was the trigger in
our patient and, therefore, she was started on antifungal therapy.
However, for those with HLH due to an inciting factor, additional
treatment with immunosuppressive agents should be commenced
immediately in severe cases with inadequate response to 2–3 days
specific treatment.3 In our patient, when 4 days of
of disease-
appropriate antifungal therapy did not lead to clinical improvement, we decided to add immunosuppression with dexamethasone and etoposide in an effort to halt the immune cascade. This
led to a dramatic improvement in the patient’s clinical status and
subsequent withdrawal of immunosuppression while continuing
the definitive treatment (antifungals) directed at the cause (disseminated histoplasmosis).
Twitter Sunny Rajendra Kumar Singh @SunSinghMD
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Patient’s perspective
This all started with fevers. I just thought that I had a sinus
infection. I went to the doctor and received antibiotics 2 days
prior to being hospitalised. I am unclear as to most of the testing
and diagnosing that took place. I do not remember anything
until I woke up on the vent at Henry Ford. I appreciate everything
done for me during my hospital stay. My recovery has been hard,
but I can now walk and do more things for myself. Thank you for
everything.

Learning points
►► Haemophagocytic lymphohistiocytosis (HLH) in adults is

most commonly due to acquired factors and an underlying
infection is the culprit in a significant proportion of cases.
►► Meticulous search for reversible inciting factors in this cohort
of patients is of paramount importance.
►► Prompt institution of treatment directed towards the inciting
factor is the core principle of treating secondary HLH.
►► Timely institution of immune suppression aimed at taming
the lethal immune cascade in those not responding to
definitive treatment may be lifesaving.
►► Use of immune suppression in HLH secondary to infection
may appear counterproductive; however, in the case
presented above, it resulted in a favourable outcome.
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